MediWound provides bromelain‑based enzymatic debridement solutions that selectively dissolve necrotic eschar while preserving viable tissue, offering a non‑surgical alternative for severe burns and chronic wounds. Its FDA‑approved product NexoBrid is used in hospital burn units, and the Phase III candidate EscharEx targets venous leg and diabetic foot ulcers to accelerate wound closure and reduce treatment costs.
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with severe burns or chronic, hard‑to‑heal wounds require surgical debridement to remove necrotic eschar, a process that is invasive, costly, and can damage surrounding viable tissue, leading to delayed healing and higher healthcare expenditures.
Solution
MediWound delivers enzymatic therapeutics that selectively dissolve necrotic tissue while sparing healthy tissue, providing a non‑surgical alternative to traditional debridement. The platform leverages a proprietary, bromelain‑enriched enzyme mixture derived from pineapple stems, formulated for topical application as a wound‑cleansing solution or dressing. NexoBrid® is an FDA, EMA and PMDA‑approved biologic for deep partial‑ and full‑thickness burns, and the pipeline candidate EscharEx® is in Phase III trials for venous leg ulcers and diabetic foot ulcers. By enabling rapid, precise eschar removal, these products accelerate wound closure, improve functional outcomes, and reduce the need for operative intervention, thereby lowering overall treatment costs. MediWound’s vertically integrated model—from plant‑based enzyme extraction through cGMP‑certified manufacturing to global commercialization—ensures consistent product quality and broad market access.
Target Audience
The primary customers are hospital burn units and wound‑care clinics treating hospitalized burn patients, as well as clinicians and healthcare systems managing chronic wounds such as venous leg ulcers and diabetic foot ulcers.
Features
- Proprietary bromelain‑enrichment technology that isolates and stabilizes plant‑derived proteolytic enzymes for maximal therapeutic activity.
- Selective enzymatic debridement that targets non‑viable eschar while preserving underlying viable tissue.
- Topical formulation designed for single‑daily application as a wound‑cleansing solution or impregnated dressing.
- NexoBrid®: FDA, EMA and PMDA‑approved orphan biologic for severe thermal burns, indicated for both adult and pediatric patients.
- EscharEx®: Next‑generation bromelain‑based therapy in Phase III development for venous leg ulcers and diabetic foot ulcers, with demonstrated safety and efficacy in Phase II trials.
- cGMP‑certified aseptic manufacturing process ensuring sterility, batch‑to‑batch consistency, and scalability for global distribution.
- Integrated analytical and quality‑control pipelines for precise enzyme characterization and potency verification.
- Strategic commercial partnerships (e.g., Vericel Corp in the U.S., direct sales in Europe, collaborations in Japan, Australia, and other markets) to facilitate worldwide product rollout.